Last checked at 
(Alliance News) - Omega Diagnostics Group PLC on Tuesday confirmed leader of its UK Rapid Test consortium Abingdon Health PLC is working with the Medicines & Healthcare Products Regulatory Agency to secure approval for the home use and self-test of its AbC-19 Covid test.
The York, England-based diagnostics company for the healthcare sector said the product received a CE marking for professional use back in July.
It noted that while the UK Department of Health and Social Care has the option to cancel its supply of goods contract - which ends on February 14, 2021 - with Abingdon Health if a CE mark had not been granted for home use by December 25, it is continuing to "work constructively" to enable authorisation.
Abingdon Health added it is liaising with regulators in 27 territories to potentially allow for future use of the AbC-19 Rapid Test outside of the UK, and has registered the test with the Maltese Medicines Authority.
Omega Chief Executive Colin King said: "We remain confident that the AbC-19 Rapid Test has a potential global application and we are delighted that the UK-RTC maintains constructive dialogue with interested customers and regulatory authorities across the world."
Shares in Omega were up 4.9% at 65.03 pence and shares in Abingdon Health were down 1.5% at 96.00 pence in London on Tuesday.
By Zoe Wickens; zoewickens@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
